Fang Baijun, Li Ning, Song Yongping, Li Jing, Zhao Robert Chunhua, Ma Yuanfang
Henan Tumor Hospital, Henan Institute of Haematology, Zhengzhou, China.
Pediatr Transplant. 2009 Jun;13(4):499-502. doi: 10.1111/j.1399-3046.2008.01002.x. Epub 2008 Jul 30.
MSC have been suggested to be the precursor cells in the bone marrow stroma that provide a scaffold and promote hematopoiesis. They have therefore been suggested to enhance engraftment after autologous and allogeneic HSC transplantation. In patients undergoing transplantation, MSC infusion was shown to be safe and to enhance engraftment of HSC, as well as to reduce the incidence of both acute and chronic GVHD. We cotransplanted haploidentical AMSC with HLA-identical sibling-matched PBSC in two pediatric patients with refractory SAA after primary or secondary graft failure. At present, the two patients are more than two yr after cotransplantation without any treatment, transfusion-independent and in good condition. Thus, cotransplantation of MSC might enhance engraftment of HSC in patients regrafted for graft failure.
间充质干细胞（MSC）被认为是骨髓基质中的前体细胞，可提供支架并促进造血作用。因此，有人提出它们可增强自体和异基因造血干细胞移植后的植入。在接受移植的患者中，输注MSC被证明是安全的，可增强造血干细胞的植入，并降低急性和慢性移植物抗宿主病（GVHD）的发生率。我们将单倍体相合的羊膜间充质干细胞（AMSC）与 HLA 相同的同胞匹配外周血干细胞（PBSC）共同移植给两名原发性或继发性移植物失败后难治性重型再生障碍性贫血（SAA）的儿科患者。目前，这两名患者在共同移植后已超过两年，无需任何治疗，不依赖输血且状况良好。因此，MSC的共同移植可能会增强移植失败后再次移植患者造血干细胞的植入。
